Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion- positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1
Lin, J. J. Drilon, A. E. Cho, B. C. Felip, E. De Langen, A. Yang, N. Kim, S. W. Lu, S. Kao, S. C. H. Velcheti, V.
Lin, J. J.
Drilon, A. E.
Cho, B. C.
Felip, E.
De Langen, A.
Yang, N.
Kim, S. W.
Lu, S.
Kao, S. C. H.
Velcheti, V.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Lin JJ, Drilon AE, Cho BC, Felip E, De Langen A, Yang N, et al. Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion- positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003685.